CONFIDENTIAL — APPROVED FOR PUBLIC RELEASE · BUREAU FILE COPY RECORDS CURRENT AS OF 29 MAY 2026 · DISTRIBUTION: UNRESTRICTED
VendorInvestigator Independent Testing Bureau · Public Records Division
DOCKET YEAR 2026 · VOL. II
35,156 SAMPLES ON FILE
No fee · No favor
Compound Evidence File
#EC-2026-0912

MAPA (methyl alpha-phenylacetoacetate) CAS 101-97-3

Filed under Raw Materials. The bureau holds 106 laboratory returns for this compound from 32 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.

Cross-Index

Subjects Shipping This Compound

32 SUBJECTS
SubjectGradeSamplesMeanMinMaxFirst seenLast seen
HomopeptideCASE #VI-2026-0760 A 6 10.0 9.9 10.0 24 May 2026 24 May 2026
Tianjin Finder Chemical TFCCASE #VI-2026-0693 A 6 10.0 9.9 10.0 14 Nov 2025 16 Apr 2026
WuXi TIDESCASE #VI-2026-0335 A 5 10.0 9.9 10.0 5 Dec 2025 26 Jun 2026
Shanghai ERP BiotechnologyCASE #VI-2026-0936 A 4 10.0 9.9 10.0 6 Mar 2026 28 Jun 2026
JEEP PeptidesCASE #VI-2026-0457 A 4 10.0 10.0 10.0 23 Dec 2025 23 Jun 2026
Sigma-AldrichCASE #VI-2026-0829 A 4 10.0 9.9 10.0 10 Mar 2026 22 Jun 2026
QYAOBIOCASE #VI-2026-0861 A 3 10.0 9.9 10.0 14 Nov 2025 8 Jul 2026
BachemCASE #VI-2026-0314 A 3 10.0 10.0 10.0 12 Nov 2025 1 May 2026
Mokemei BiotechnologyCASE #VI-2026-0540 A 3 10.0 10.0 10.0 2 Jun 2026 11 Jun 2026
Flourishglobal PeptideCASE #VI-2026-0630 A 3 10.0 10.0 10.0 6 Jan 2026 7 Apr 2026
Shanghai Sigma AudleyCASE #VI-2026-0505 A 3 10.0 9.9 10.0 7 May 2026 23 Jun 2026
Thermo Fisher ScientificCASE #VI-2026-0142 A 3 10.0 10.0 10.0 1 Feb 2026 15 Aug 2026
AsymchemCASE #VI-2026-0091 A 3 10.0 9.9 10.0 26 Apr 2026 5 Jun 2026
Chimera PeptidesCASE #VI-2026-0260 X 1 10.0 10.0 10.0 20 Jun 2025 20 Jun 2025
GenScript PeptidesCASE #VI-2026-0860 A 4 9.9 9.9 10.0 2 Feb 2026 16 May 2026
AmbioPharmCASE #VI-2026-0177 A 4 9.9 9.9 10.0 6 Mar 2026 9 Jul 2026
Kerui PeptidesCASE #VI-2026-0626 A 3 9.9 9.9 10.0 9 Feb 2026 11 May 2026
Hubei JianxiangCASE #VI-2026-0048 A 3 9.9 9.9 10.0 24 Apr 2026 15 Jun 2026
Chinese Peptide CompanyCASE #VI-2026-0184 A 3 9.9 9.9 10.0 15 Jun 2026 1 Jul 2026
PolyPeptide GroupCASE #VI-2026-0143 A 3 9.9 9.9 10.0 10 Feb 2026 19 May 2026
SinoPepCASE #VI-2026-0387 A 3 9.9 9.9 10.0 8 Feb 2026 12 Jul 2026
Sangon BioCASE #VI-2026-0671 A 2 9.9 9.9 10.0 22 Feb 2026 7 Jun 2026
Shanghai Wibson BiotechnologyCASE #VI-2026-0379 A 2 9.9 9.9 10.0 27 Apr 2026 14 May 2026
Hybio PharmaceuticalCASE #VI-2026-0065 A 2 9.9 9.9 9.9 27 Feb 2026 2 May 2026
Shanghai Sigma Audley SSACASE #VI-2026-0486 A 6 8.9 8.2 10.0 24 May 2026 24 May 2026
Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 A 3 8.7 7.7 10.0 24 May 2026 24 May 2026
Glbiochem (Shanghai)CASE #VI-2026-0704 A 6 8.2 6.7 10.0 24 May 2026 24 May 2026
Xian Yihang TechnologyCASE #VI-2026-0656 X 1 8.1 8.1 8.1 11 Jun 2025 11 Jun 2025
Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 A 5 7.5 6.3 8.3 23 May 2026 23 May 2026
Qingdao Sigma Chemical QSCCASE #VI-2026-0538 A 3 7.0 6.6 7.4 21 May 2026 21 May 2026
Astro PeptidesCASE #VI-2026-0424 X 1 5.3 5.3 5.3 2 Apr 2025 2 Apr 2025
Wuhan Newtop BiotechCASE #VI-2026-0676 X 1 0.0 0.0 0.0 3 Jun 2025 3 Jun 2025

Open any subject to view the batch-level evidence for MAPA (methyl alpha-phenylacetoacetate) CAS 101-97-3 alone.